» Articles » PMID: 19260109

Detection of CpG Island Hypermethylation of Caspase-8 in Neuroblastoma Using an Oligonucleotide Array

Overview
Date 2009 Mar 5
PMID 19260109
Citations 4
Authors
Affiliations
Soon will be listed here.
Abstract

Background: The caspase-8 gene (CASP8) is frequently inactivated in unfavorable neuroblastomas through DNA methylation. The present study utilized oligoarrays to evaluate the methylation status of a CpG island located between exons 2 and 3 of caspase 8 in neuroblastomas.

Procedure: DNA derived from 70 neuroblastomas was amplified by PCR after bisulfate modification and subjected to analysis on a self-made oligoarray that utilized a polycarbodiimide-coated slide to detect methylation of six intragenic CpG islands of caspase 8. In 30 cases, the methylation status was also analyzed by sequencing. In six cases, the PCR product was cloned into a vector and analyzed.

Results: Among the 70 tumor-derived DNAs, methylation was not detected in 18 cases, one methylated CpG was found in 12 cases, two in 18 cases, three in 3 cases, four in 8 cases, five in 1 case and six in 10 cases. All methylated CpG loci detected by sequencing were detected by oligoarray, but some methylated CpGs in three loci were detected by oligoarray alone. In these discrepant loci, methylation was detected in some clones after subcloning, indicating that the oligoarray might be more sensitive than sequencing. The CASP8 expression level was depressed in the tumors having two distinct CpG doublets. These results were significantly correlated with MYCN amplification and with clinical outcomes.

Conclusions: A significant difference in the methylation status within the CpG island of CASP8 was shown between favorable and unfavorable subtypes, and CASP8 methylation detected by oligoarray may be useful in the clinical evaluation of neuroblastomas.

Citing Articles

CASP8 SNP D302H (rs1045485) is associated with worse survival in MYCN-amplified neuroblastoma patients.

Rihani A, De Wilde B, Zeka F, Laureys G, Francotte N, Tonini G PLoS One. 2014; 9(12):e114696.

PMID: 25502557 PMC: 4263607. DOI: 10.1371/journal.pone.0114696.


DNA hypomethylation affects cancer-related biological functions and genes relevant in neuroblastoma pathogenesis.

Mayol G, Martin-Subero J, Rios J, Queiros A, Kulis M, Sunol M PLoS One. 2012; 7(11):e48401.

PMID: 23144874 PMC: 3492354. DOI: 10.1371/journal.pone.0048401.


Genome-wide promoter methylation analysis in neuroblastoma identifies prognostic methylation biomarkers.

Decock A, Ongenaert M, Hoebeeck J, De Preter K, Van Peer G, Van Criekinge W Genome Biol. 2012; 13(10):R95.

PMID: 23034519 PMC: 3491423. DOI: 10.1186/gb-2012-13-10-r95.


Harnessing the cell death pathway for targeted cancer treatment.

Speirs C, Hwang M, Kim S, Li W, Chang S, Varki V Am J Cancer Res. 2011; 1(1):43-61.

PMID: 21969218 PMC: 3180107.